SNHG12 Promotes Angiogenesis Following Ischemic Stroke via Regulating miR-150/VEGF Pathway

Zhao, Mian; Wang, Jun; Xi, Xinlong; Tan, Nan; Zhang, Li

doi:10.1016/j.neuroscience.2018.08.029

Cited by 82 publications

(43 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…14 LncRNAs mediate several vital pathways in the progression of stroke. 19,20 For example, lncRNA SNHG14 can promote microglia activation through regulating miR-145-5P/PLA2G4A in stroke. 21 In addition, lncRNA MALAT1 regulates cerebrovascular pathologies and neuronal cell death in stroke.…”

Section: Introductionmentioning

confidence: 99%

<p>Exosomal Long Non-Coding RNA Expression from Serum of Patients with Acute Minor Stroke</p>

Zhuang

Chen

2020

NDT

View full text Add to dashboard Cite

These authors contributed equally to this work Background: Acute minor stroke (AMS) is one kind of hypoxic ischemic necrosis with no more than 4 National Institutes of Health Stroke Scale (NIHSS) score. However, the early diagnosis of AMS is tough for lack of effective molecular markers. Recently, many long noncoding RNAs (lncRNAs) associated with AMS have been gradually revealed. Here, we aim to find the potential biomarkers of lncRNAs in exosomes isolated from blood serum of patients with AMS for early detection. Methods: RNA-seq technique, KEGG pathway analysis and GO enrichment analysis were used in this study. Besides, reverse transcription real-time quantitative polymerase chain reaction (RT-qPCR) was used to validate expression levels of four of eleven differentially expressed lncRNAs (lnc-CRKL-2, lnc-NTRK3-4, RPS6KA2-AS1 and lnc-CALM1-7) involved in the neurotrophin signaling pathway. Results: The expression levels of lnc-CRKL-2 (mean value 48, standard deviation 4.583, P = 0.003) and lnc-NTRK3-4 (mean value 32.3, standard deviation 2.08, P = 0.001) were increased significantly in AMS patients, while the expression levels of RPS6KA2-AS1 (mean value −118.7, standard deviation 7.09, P = 0.001) and lnc-CALM1-7 (mean value −148.7, standard deviation 6.10, P = 0.001) were decreased dramatically. Conclusion: In conclusion, these four new revealed lncRNAs may be used as novel joint biomarkers for the early detection of AMS.

show abstract

Section: Introductionmentioning

confidence: 99%

<p>Exosomal Long Non-Coding RNA Expression from Serum of Patients with Acute Minor Stroke</p>

Zhuang

Chen

2020

NDT

View full text Add to dashboard Cite

show abstract

“…Clorf79, also known as SNHG12, is a novel lncRNA identi ed to be upregulated in several cancer cells, such as human osteosarcoma cell [33], nasopharyngeal carcinoma cell [34], and human endometrial carcinoma [35]. Zhao et al [36] veri ed that SNHG12 promotes angiogenesis after ischemic stroke through the miR-150/VEGF pathway, that further clari ed the mechanism of angiogenesis after ischemic stroke, and provided a target for the treatment of ischemic stroke. Wang et al [37] suggested that SNHG12 contributes to the oncogenic potential of triple-negative breast cancer and may be a promising therapeutic target.…”

Section: Discussionmentioning

confidence: 99%

Small Nucleolar RNA and Small Nucleolar RNA Host Gene Signatures as Biomarkers for Pancreatic Cancer

Han

Xie

Yang

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: The objective of this study was to identify key molecules including small nucleolar RNAs (snoRNAs) and small nucleolar RNA host genes (SNHGs) involved in pancreatic cancer.Methods: First, we screened the differentially expressed snoRNAs (DEsnoRNAs) and trend-related snoRNAs based on the cancer genome atlas (TCGA) dataset for pancreatic cancer, and then performed methylation correlation analysis, survival analysis, and extraction of snoRNA host genes for Gene ontology (GO) functional and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Next, DESNHGs and trend-related SNHGs were screened according to the TCGA dataset for pancreatic cancer, and a competing endogenous RNA (ceRNA) network was constructed for pathway and functional enrichment analysis. Results: A total of eight DEsnoRNAs and 93 trend-related snoRNAs were extracted. Then, ten host genes of the snoRNAs were identified. Functional analysis suggested that the ten host genes were significantly enriched in several GO terms including mitotic chromosome condensation and endocytosis pathway. SNORA38B was considered to associate with survival and prognosis. The SNORD17 and SNORA11 were considered to negatively correlate with methylation. In addition, two trend-related SNHGs were extracted. Additionally, a ceRNA network was constructed with 11 miRNAs, one lncRNAs, and one mRNA. SNHG24 mainly correlated with GnRH secretion and neuroactive ligand-receptor interaction in pancreatic cancer. Conclusion: The identified snoRNAs and SNHGs could serve as potential markers for the early detection of pancreatic cancer.

show abstract

“…SNHG12 is negative regulation miR-195-5p, miR-320, miR-129, miR-193a-3p, microRNA-199a/b-5p and miR-424-5 [11,14,15,17,26] . Yin, Zhao and Long found that SNHG12 regulates brain microvascular endothelial cell death, the in ammatory response, and angiogenesis during and after ischemic stroke through target genes and signaling pathways (Sirt1, AMPK signaling pathway, and miR-150/VEGF pathway) [38][39][40] . In addition, the expression level of SNHG12 in gastric cancer, osteoma, colon cancer, hepatocellular carcinoma and various other tumors is related to the clinical features and prognosis of cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Long Noncoding RNA SNHG12 is a Potential Diagnostic and Prognostic Biomarker in Various Tumors

Wang

Jiang

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Tumors are the second most common cause of death in humans worldwide, second only to cardiovascular and cerebrovascular diseases. Although methods and techniques for the treatment of tumors continue to improve, the effect is not satisfactory. These may lack effective therapeutic targets. This study aimed to evaluate the value of SNHG12 as a biomarker in the prognosis and clinical characteristics of various cancer patients.Methods. We analyzed SNHG12 expression and plotted the survival curves of all cancer samples in the TCGA database using the GEPIA tool. Then, we searched for eligible papers up to April 1, 2019 in databases. Next, the data were extracted from studies examining SNHG12 expression, overall survival and clinicopathological features in patients with malignant tumors. We used Review Manager 5.3 and Stata 15 software to analyze the statistical data.Results. In the TCGA database, abnormally high expression of SNHG12 in tumor samples indicates that the patient has a poor prognosis. Results of meta-analysis is that SNHG12 high expression is related to low overall survival (HR=2.72, 95% CI=1.95-3.8, P<0.00001), high tumor stage (OR=3.94, 95% CI=2.80-5.53, P<0.00001), high grade (OR=2.04, 95% CI=1.18-3.51, P=0.01), distant metastasis (OR=2.20, 95% CI=1.40-3.46, P=0.0006), tumor size (OR=2.79, 95% CI=1.89-4.14, P<0.00001) and lymph node metastasis (OR=2.66, 95%CI=1.65-4.29, P<0.0001).Conclusions. Our study confirmed that the high expression level of SNHG12 is closely related to the clinicopathological characteristics and prognosis of patients and is a new predictive biomarker for various cancer patients.

show abstract

SNHG12 Promotes Angiogenesis Following Ischemic Stroke via Regulating miR-150/VEGF Pathway

Cited by 82 publications

References 27 publications

<p>Exosomal Long Non-Coding RNA Expression from Serum of Patients with Acute Minor Stroke</p>

<p>Exosomal Long Non-Coding RNA Expression from Serum of Patients with Acute Minor Stroke</p>

Small Nucleolar RNA and Small Nucleolar RNA Host Gene Signatures as Biomarkers for Pancreatic Cancer

Long Noncoding RNA SNHG12 is a Potential Diagnostic and Prognostic Biomarker in Various Tumors

Contact Info

Product

Resources

About